Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD, and was promoted to a Senior Research Fellow in 2020. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of patentable, highly potent and selective, and orally active enzyme inhibitors for targeted cancer therapy.
About me
Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD, and was promoted to a Senior Research Fellow in 2020. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of patentable, highly potent and selective, and orally active enzyme inhibitors for targeted cancer therapy.
About me
Research
Excludes commercial-in-confidence projects.
New treatment for childhood leukaemia, Channel 7 Children's Research Foundation of SA, 01/01/2016 - 31/12/2016
Discovery of CDK6 inhibitors for treatment of childhood medulloblastoma, Channel 7 Children's Research Foundation of SA, 01/01/2015 - 31/12/2016
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2023 |
Open access
2
2
11
|
2023 |
3
1
1
|
2023 |
Open access
3
|
2023 |
Open access
2
|
2022 |
Open access
15
11
2
|
2021 |
Open access
7
8
|
2021 |
|
2021 |
Open access
7
6
1
|
2021 |
Open access
5
3
|
2021 |
Open access
11
7
1
|
2020 |
8
10
1
|
2020 |
40
32
7
|
2019 |
6
5
|
2019 |
Open access
10
7
3
|
2019 |
Open access
36
30
|
2018 |
74
67
13
|
2018 |
Open access
18
16
3
|
2017 |
Open access
22
18
|
2017 |
14
15
2
|
2017 |
Open access
32
29
|
2017 |
Open access
11
10
2
|
2017 |
Open access
57
48
9
|
2016 |
20
18
|
2016 |
Open access
21
20
3
|
2016 |
14
12
|
2016 |
Open access
55
46
5
|
2016 |
Open access
15
12
|
2016 |
Open access
39
35
|
2015 |
Open access
|
2015 |
35
33
9
|
2015 |
Open access
15
15
|
2015 |
Open access
27
22
6
|
2015 |
29
25
4
|
2015 |
34
33
3
|
2015 |
Open access
97
82
|
2014 |
Open access
83
74
10
|
2014 |
Open access
70
62
1
|
2014 |
Open access
26
18
3
|
2014 |
40
36
6
|
2013 |
Open access
11
11
|
2013 |
Open access
19
17
|
2011 |
34
34
|
2010 |
9
8
|
2010 |
14
13
|
2009 |
|
Research
Details | Registry | Status |
---|---|---|
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds Wang, Shudong; Zeleke, Solomon Tadesse; Yu, Mingfeng |
WO | Filed |
External engagement & recognition
Organisation | Country |
---|---|
Ain Shams University | EGYPT |
Cardiff University | UNITED KINGDOM |
CSIRO Australia (Commonwealth Scientific Industrial Research organisation) | AUSTRALIA |
Griffith University | AUSTRALIA |
Lebanese American University | LEBANON |
National Research Centre | EGYPT |
Newcastle University, United Kingdom | UNITED KINGDOM |
Open University | UNITED KINGDOM |
Shanghai Jiao Tong University | CHINA |
University College London | UNITED KINGDOM |
University of Adelaide | AUSTRALIA |
University of Newcastle | AUSTRALIA |
University of Nottingham | UNITED KINGDOM |
University of Oxford | UNITED KINGDOM |
University of Potsdam | GERMANY |
University of South Australia | AUSTRALIA |
University of Southampton | UNITED KINGDOM |
University of Sydney | AUSTRALIA |
Westmead Hospital | AUSTRALIA |
Yabao Pharmaceutical Group Co., Ltd | CHINA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Chartered MemberRoyal Australian Chemical Institute (RACI) |
2018 |
MemberAmerican Association for the Advancement of Science (AAAS) |
2018 |
MemberAmerican Association for Cancer Research (AACR) |
2018 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Design and synthesis of mnk Inhibitors for targeted cancer therapy | Current |
Evaluation of the cyclin-dependent kinase CDK inhibitors resistance for cancer treatment | Current |
Derivatives of 4-(1H-pyrazol-4-yl)pyrimidine CDK2 inhibitors as potential anticancer agents: design, synthesis & evaluation | Completed |
Design, synthesis, and evaluation of novel CDK2 inhibitors as potential anticancer agents | Completed |
Discovery of cyclin-dependent kinase 2/5 inhibitors for the potential treatment of cancer | Completed |
Discovery of novel inhibitors of MAPK-interacting kinases as anti-tumour agents | Completed |
Novel inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents: design, synthesis and evaluation | Completed |
Protein kinase inhibitors as potential anti-cancer agents: design, synthesis and evaluation | Completed |